Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.87 +0.32 (+0.85%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist

Price and Volume

Volume	440,348
Open	37.55
Bid (Size)	37.50 (300)
Ask (Size)	39.99 (100)
Prev. Close	37.55
Today's Range	37.20 - 37.92
52wk Range	25.52 - 40.93
Shares Outstanding	57,031,297
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case ↗

January 06, 2026

Via Chartmill

Performance

YTD	+1.3%	+1.3%
1 Month	-2.7%	-2.7%
3 Month	+42.6%	+42.6%
6 Month	+10.4%	+10.4%
1 Year	+7.6%	+7.6%

More News

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗

December 18, 2025

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Preview For Harmony Biosciences ↗

November 03, 2025

Via Benzinga

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? ↗

October 23, 2025

Via Stocktwits

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

December 16, 2025

From Beacon Biosignals

Via GlobeNewswire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case ↗

December 12, 2025

Via Chartmill

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

December 08, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

December 02, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Growth at a Reasonable Price ↗

November 26, 2025

Via Chartmill

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

November 24, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

November 19, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Upcoming Investor Conferences

November 18, 2025

From Harmony Biosciences

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals ↗

November 15, 2025

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction ↗

November 04, 2025

Via Chartmill

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

November 04, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price ↗

October 29, 2025

Via Chartmill

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

October 23, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case ↗

October 20, 2025

Via Chartmill

Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts

October 23, 2025

Via MarketMinute

Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup ↗

October 16, 2025

Via Chartmill

Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗

October 06, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity ↗

September 26, 2025

Via Chartmill

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?

Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.

What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?

Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?

The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market

What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?

The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 37.87

When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?

The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 01/08/26 04:00 PM ET

What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?

The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 2.16B

How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?

Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.